Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many NHS patients in England have been treated with Evusheld to date; and when will that drug become generally available on prescription to those with immunosuppressed conditions to protect against covid-19.

To date, Evusheld has not been made available to National Health Service patients. Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant.

The UK Health Security Agency is testing the efficacy of Evusheld against the Omicron variant and we are identifying appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. Determining the efficacy of Evusheld against the Omicron variant will be necessary prior to any procurement or deployment decisions.